全文获取类型
收费全文 | 3774篇 |
免费 | 242篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 42篇 |
儿科学 | 102篇 |
妇产科学 | 41篇 |
基础医学 | 707篇 |
口腔科学 | 57篇 |
临床医学 | 350篇 |
内科学 | 800篇 |
皮肤病学 | 43篇 |
神经病学 | 362篇 |
特种医学 | 97篇 |
外科学 | 531篇 |
综合类 | 69篇 |
一般理论 | 30篇 |
预防医学 | 323篇 |
眼科学 | 34篇 |
药学 | 219篇 |
中国医学 | 1篇 |
肿瘤学 | 218篇 |
出版年
2021年 | 36篇 |
2020年 | 30篇 |
2019年 | 43篇 |
2018年 | 57篇 |
2017年 | 57篇 |
2016年 | 60篇 |
2015年 | 56篇 |
2014年 | 77篇 |
2013年 | 118篇 |
2012年 | 152篇 |
2011年 | 175篇 |
2010年 | 107篇 |
2009年 | 102篇 |
2008年 | 200篇 |
2007年 | 187篇 |
2006年 | 191篇 |
2005年 | 179篇 |
2004年 | 166篇 |
2003年 | 163篇 |
2002年 | 179篇 |
2001年 | 89篇 |
2000年 | 95篇 |
1999年 | 78篇 |
1998年 | 59篇 |
1997年 | 62篇 |
1996年 | 53篇 |
1995年 | 46篇 |
1994年 | 37篇 |
1993年 | 30篇 |
1992年 | 63篇 |
1991年 | 98篇 |
1990年 | 60篇 |
1989年 | 63篇 |
1988年 | 53篇 |
1987年 | 69篇 |
1986年 | 67篇 |
1985年 | 63篇 |
1984年 | 58篇 |
1983年 | 50篇 |
1982年 | 60篇 |
1981年 | 32篇 |
1979年 | 40篇 |
1978年 | 25篇 |
1977年 | 22篇 |
1975年 | 27篇 |
1974年 | 29篇 |
1972年 | 23篇 |
1971年 | 32篇 |
1969年 | 21篇 |
1967年 | 20篇 |
排序方式: 共有4026条查询结果,搜索用时 15 毫秒
1.
2.
3.
Olle Zetterström Christer Andersson Leif Eriksson ers Fredriksson Johan Friskopp Gunnar Heden Bernt Jansson Tord Lundgren Rolf Nilveus ers Olsson Stefan Renvert Lars Salonen Lars Sjöström ers Winell ers Östgren Stina Gestrelius 《Journal of clinical periodontology》1997,24(9):697-704
Abstract The aim of the present clinical trial was to test tolerability during 2 treatments with EMDOGAIN® in a large number of patients. An open, controlled study design in 10 Swedish specialist clinics was chosen, with a test group of 107 patients treated with EMDOGAIN® in connection with periodontal surgery at 2 surgical test sites per patient. The procedures were performed 2 to 6 weeks apart on one-rooted teeth with at least 4 mm deep intraosseous lesions. A control group of 33 patients underwent flap surgery without EMDOGAIN® at I comparable site. In total 214 test and 33 control surgeries were performed. Serum samples were obtained from test patients for analysis of total and specific antibody levels. 10 of the patients had samples taken before and after the first surgery. 56 other samples were taken after one treatment with EMDOGAIN®, and 63 after 2 treatments. None of the samples, not even from allergy-prone patients after 2 treatments, indicated deviations from established baseline ranges. This indicates that the immunogenic potential of EMDOGAIN® is extremely low when applied in conjunction with periodontal surgery. Comparison between the test and control groups demonstrated the same type and frequency of post-surgical experiences, i.e., reactions caused by the surgical procedure itself. Clinical probing and radiographic evaluation was performed at baseline and 8 months postsurgery. About half of the patients (44 test and 21 control) were also evaluated after 3 years. There was a significant difference between the test and control results at 8 months post surgery. and this difference had increased further at the 3 year follow-up. The 2.5–3 mm increase in attachment and bone level after treatment with EMDOGAIN® was of the same magnitude as seen in the studies with split-mouth design aiming for lest of effectiveness of EMDOGAIN®. 相似文献
4.
Clonidine (10 micrograms X kg-1) reduced by almost 50% the increase in plasma neuropeptide (NPY)-like immunoreactivity (-LI) induced by preganglionic nerve stimulation at 8 Hz. This effect was reversed by yohimbine (1 mg X kg-1) which caused a three-fold increase of the plasma NPY-LI. Prazosin (1 mg X kg-1) had no such effect. Guanethidine (5 mg X kg-1) reduced the stimulation-evoked increase in plasma NPY-LI. It is concluded that the release of NPY-LI evoked by nerve stimulation from sympathetic nerve terminals is controlled by a presynaptic alpha 2-adrenoceptor-mediated mechanism. 相似文献
5.
6.
7.
8.
Per H. Morberg Olle G. P. Isaksson Carina B. Johansson Jonas Sandstedt Jan F. T rnell 《Acta orthopaedica》1997,68(4):344-348
Several recent studies have investigated the effects of growth hormone (GH) on the healing of fractures and bone ingrowth, but with conflicting results. The negative results may be due to antibody formation against injected GH or because some experimental models are able to prove only positive GH effects. In this study, we wanted to investigate the effect of GH on implant integration in bone. To avoid potential formation of antibodies against injected GH, we used a model with transgenic mice overexpressing bovine GH (bGH).
Titanium implants were inserted in the forehead of the mice. 4 months after insertion, the implants were cut out en bloc with the surrounding bone. The calcified specimens were cut and ground to a thickness of approximately 10m. Histomorphometry demonstrated significantly more direct bone-to-metal contact in the transgenic mice than in the nontransgenic littermates. Our findings indicate that systemic administration of GH in humans may improve implant integration in bone. 相似文献
Titanium implants were inserted in the forehead of the mice. 4 months after insertion, the implants were cut out en bloc with the surrounding bone. The calcified specimens were cut and ground to a thickness of approximately 10m. Histomorphometry demonstrated significantly more direct bone-to-metal contact in the transgenic mice than in the nontransgenic littermates. Our findings indicate that systemic administration of GH in humans may improve implant integration in bone. 相似文献
9.
Occurrence of anti-C1q antibodies in IgA nephropathy 总被引:1,自引:0,他引:1
Gunnarsson I; Ronnelid J; Lundberg I; Jacobson S 《Nephrology, dialysis, transplantation》1997,12(11):2263-2268
Background: The pathogenic mechanisms and the antigens
involved in the establishment and progress of IgA nephropathy are unknown.
As antibodies against C1q have been reported to correlate with SLE
nephritis, we analysed the occurrence of these antibodies in IgA
nephropathy in order to investigate the possibility of pathogenetic
similarities in these renal disorders. Methods: The
occurrence of IgA- and IgG anti-C1q antibodies (anti-C1q) were determined
by ELISA in patients with IgA nephropathy (n=36) and SLE nephritis (n=37),
diseases both known to be associated with circulating immune complexes.
Levels of these antibodies were also determined in two other glomerular
diseases, i.e. idiopathic membranous glomerulo-nephritis (n=7) and minimal
change disease (n=2), in which circulating immune complexes are usually not
present, and in 40 healthy controls. Results: IgA
anti-C1q was observed in increased titres in 11/36 of the patients with IgA
nephropathy, in 2/37 of the patients with SLE nephritis (both with
proliferative disease) and in 1/9 of the patients with membranous and
minimal change disease (P<0.001). Increased titres of IgG anti-C1q
were observed in 1/36 of the patients with IgA nephropathy, in 17/37 of the
patients with SLE nephritis and in 0/9 of the patients with membranous and
minimal change disease (P<0.001). There were no correlations between
the levels of anti-C1q antibodies and clinical parameters such as degree of
proteinuria, haematuria, or renal function. Nor was there any correlation
to the concentration of C3a and the terminal complement complex (TCC) in
patients with IgA nephropathy. Conclusions: The
occurrence of anti-C1q antibodies in both IgA nephropathy and SLE
nephritis, albeit of different predominating isotypes, indicates the
possibility of a similar pathogenic mechanism involved in these renal
disorders. The occurrence of IgA anti-C1q antibodies in patients with IgA
nephropathy has to our knowledge not previously been reported. 相似文献
10.
G Lindstedt E Nystr?m P A Lundberg E Johansson R Eggertsen 《Scandinavian journal of primary health care》1992,10(3):192-197
In order to assess the diagnostic outcome of a screening for primary hyperparathyroidism (PHPT) in an elderly population, we determined ionized calcium in serum from 368 individuals participating in a health control at M?lnlycke Primary Care Centre (200 women, 168 men; age range 75-95 years); four-fifths of the individuals living in their homes, the remainder in homes for aged or nursing homes. Intact parathyroid hormone was determined in the samples with oinized calcium concentration greater than mean + 3SD of the truncated population sample, and these individuals were also recalled for another blood sample. Moderate hypercalcaemia, probably due to PHPT, was found in eight individuals (2% of the complete sample, 3% of the women), five having neuropsychiatric or neuromuscular symptoms consistent with PHPT. Surgical intervention is probably indicated in only a small proportion of elderly patients. We conclude that optimal benefits in relation to costs of screening for PHPT in old people will depend on the availability of a safe and simple pharmacological treatment that could determine any causal relationship between hypercalcaemia and symptoms. 相似文献